

Table S5. Clinical characteristics of patients with versus without SAD

Clinical variable	Patients with SAD (n=63)	Patients without SAD (n= 89)	p-value
Age [yrs]	58.9 (48.90, 66.9)	50.9 (42.7, 57.4)	0.002
BMI [Kg/m ²]	27.4 (24.5, 31.3)	27.0 (24.38, 30.46)	0.367
Adult onset asthma, n	42 (67%)	59 (66%)	0.992
Female, n	28 (44%)	56 (63%)	0.036
Current or former smokers ≥10PY, n	21 (33%)	18 (20%)	0.102
Atopy, blood and sputum differential counts			
Atopy, n	35 (56%)	53 (62%)	0.582
Blood eosinophil granulocytes [1000/μl]	0.29 (0.16, 0.58)	0.30 (0.14, 0.48)	1
Blood neutrophil granulocytes [1000/μl]	4.56 (3.34, 6.71)	4.25 (3.37, 5.31)	0.349
Sputum eosinophil granulocytes [%]	3.20 (0.80, 15.70)	1.35 (0.33, 4.38)	0.031
Sputum neutrophil granulocytes [%]	56.70 (33.30, 76.10)	55.10 (30.90, 69.80)	0.548
Asthma severity			
Mild-moderate asthma, n	27 (43%)	64 (72%)	0.001
Severe asthma, n	36 (57%)	25 (28%)	0.001
Asthma control questionnaire (ACQ)	2.0 (1.0, 3.3)	1.1 (0.6, 2.3)	<0.001
Asthma quality of life questionnaire (AQLQ)	4.94 (4.02, 5.97)	5.66 (4.46, 6.28)	0.046
Patients with ≥ 1 severe exacerbation, n	40 (64%)	40 (45%)	0.037
GINA control status			
Controlled, n	12 (19%)	36 (41%)	0.004
Partly controlled, n	18 (29%)	28 (32%)	0.004
Uncontrolled, n	33 (52%)	25 (28%)	0.004
Lung function			
Patients with R5-R20 > ULN	63 (100%)	0 (0%)	<0.001
Patients with AX > ULN	56 (90%)	14 (16%)	<0.001
FEV ₁ [z-score]	-2.43 (-3.17, -1.70)	-0.98 (-1.69, -0.06)	<0.001
FEV ₁ /FVC [z-score]	-2.67 (-3.52, -1.74)	-1.26 (-1.89, -0.55)	<0.001
FEF ₂₅₋₇₅ [z-score]	-2.72 (-3.15, -1.58)	-1.24 (-1.91, -0.47)	<0.001
FeNO [ppb]	30.0 (16.5, 44.5)	25.5 (15.0, 41.8)	0.557
Medication			
ICS (Fluticasone-equivalent) [μg/d]	670 (510)	430 (440)	0.001
LTRA, n	11 (18%)	13 (15%)	0.803
LABA, n	56 (89%)	71 (80%)	0.204

LAMA, n	21 (33%)	14 (16%)	0.019
Oral corticosteroids, n	20 (32%)	16 (18%)	0.076
Omalizumab, n	2 (3%)	3 (3%)	1
Mepolizumab, n	1 (2%)	1 (1%)	1

TABLE S5. Clinical characteristics of patients with versus without SAD. Data is presented as median (25%, 75% IQR), and number (%). Yrs, years, n, number of patients; BMI, Body Mass Index; PY, pack-years; GINA, Global Initiative for Asthma; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality Of Life Questionnaire; R5–R20, resistance at 5 Hz – resistance at 20 Hz [kPa/l/s]; AX, reactance area [kPa/l/s]; ULN, upper limit of normal; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1/FVC, FEV1 as % of FVC; FEF25-75, forced expiratory flow at 25% - 75% of FVC; FeNO, fractional exhaled nitric oxide; ppb, parts per billion; LTRA, leukotriene antagonist; LABA, long-acting β 2 agonist; LAMA, long-acting muscarinic antagonist.